Pharmacokinetics, Safety, and Tolerability of Ertugliflozin (MK-8835/PF-04971729) in Participants With Hepatic Impairment and in Healthy Participants (MK-8835-014)

Inclusion Criteria:

ALL PARTICIPANTS:

- Body Mass Index (BMI) of 18 to 40 kg/m^2; and a total body weight >50 kg (110 lbs)

- Male or female not of reproductive potential

- If a female of reproductive potential, agrees to remain abstinent from heterosexual
activity or agree to use or have their partner use 2 methods of acceptable
contraception to prevent pregnancy while the participant is receiving study
medication and for 14 days after the last dose of study medication PARTICIPANTS WITH
NORMAL HEPATIC FUNCTION

- Healthy with normal hepatic function PARTICIPANTS WITH HEPATIC IMPAIRMENT

- Satisfy the criteria for Child-Pugh classification [moderate (Part 1): Child-Pugh
Scores 7-9 points, mild (Part 2): Child-Pugh Scores 5-6 points] within 14 days before
administration of study medication

- A diagnosis of hepatic impairment due to primary liver disease and not secondary to
other diseases

- Stable hepatic impairment, defined as no clinically-significant change in disease
status within the last 30 days

- On a stable dose of medication and/or treatment regimen used to manage hepatic
disease for at least 4 weeks prior to study start

Exclusion Criteria:

- ALL PARTICIPANTS

- A known hypersensitivity or intolerance to ertugliflozin or any other Sodium-Glucose
co-Transporter 2 (SGLT2) inhibitor (i.e., canagliflozin [Invokana], dapagliflozin
[Farxiga], empagliflozin, or ipragliflozin)

- Febrile illness within 5 days prior to the first dose of study medication

- Any clinically significant malabsorption condition

- A positive urine drug screen for drugs of abuse or recreational drugs

- Abuse of alcohol or binge drinking and/or any other illicit drug use or dependence
within 6 months of study start

- Treatment with an investigational drug within 30 days preceding the first dose of
study medication

- Pregnant or breastfeeding females

- Use of herbal supplements within 28 days prior to the first dose of study medication

- Blood donation (excluding plasma donations) of approximately 1 pint (500 mL) or more
within 56 days prior to dosing

- History of sensitivity to heparin or heparin-induced thrombocytopenia

- PARTICIPANTS WITH NORMAL HEPATIC FUNCTION

- Use of prescription drugs (hormonal methods of birth control are allowed), vitamins,
and dietary supplements within 7 days prior to the first dose of study medication

- Positive serology for Hepatitis B or C

- PARTICIPANTS WITH HEPATIC IMPAIRMENT

- Hepatic carcinoma and hepatorenal syndrome or life expectancy less than 1 year

- Undergone portal-caval shunt surgery

- History of gastrointestinal hemorrhage due to esophageal varices or peptic ulcers
less than one month prior to study entry

- Signs of significant hepatic encephalopathy

- Severe ascites and/or pleural effusion

- A transplanted kidney, heart or liver

- Received any of the following medications within 7 days prior to the first dose of
study medication or during the study: Other SGLT2 inhibitors (eg, dapagliflozin,
canagliflozin, empagliflozin, and ipragliflozin); Any potent drug-metabolizing
enzyme-inducing drug, including rifampin, phenytoin, and carbamazepine; Probenecid,
valproic acid, gemfibrozil